These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1785 related items for PubMed ID: 19702903

  • 1. Prevention of hepatocellular carcinoma in hepatitis B virus infection.
    Lim SG, Mohammed R, Yuen MF, Kao JH.
    J Gastroenterol Hepatol; 2009 Aug; 24(8):1352-7. PubMed ID: 19702903
    [Abstract] [Full Text] [Related]

  • 2. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF, Lai CL.
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [Abstract] [Full Text] [Related]

  • 3. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
    Kim CH, Um SH, Seo YS, Jung JY, Kim JD, Yim HJ, Keum B, Kim YS, Jeen YT, Lee HS, Chun HJ, Kim CD, Ryu HS.
    J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
    [Abstract] [Full Text] [Related]

  • 4. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.
    Asia-Pacific Working Party on Prevention of Hepatocellular Carcinoma.
    J Gastroenterol Hepatol; 2010 Apr; 25(4):657-63. PubMed ID: 20492323
    [Abstract] [Full Text] [Related]

  • 5. Management of chronic hepatitis B infection.
    Sundaram V, Kowdley K.
    BMJ; 2015 Oct 21; 351():h4263. PubMed ID: 26491030
    [Abstract] [Full Text] [Related]

  • 6. [Strategies for the prevention of hepatocellular carcinoma in the context of chronic viral hepatitis].
    Schott E, Bergk A, Berg T.
    Z Gastroenterol; 2008 Jan 21; 46(1):69-80. PubMed ID: 18188819
    [Abstract] [Full Text] [Related]

  • 7. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, HEPNET. Greece Cohort Study Group.
    Gut; 2011 Aug 21; 60(8):1109-16. PubMed ID: 21270118
    [Abstract] [Full Text] [Related]

  • 8. Hepatitis B virus: from diagnosis to treatment.
    Dény P, Zoulim F.
    Pathol Biol (Paris); 2010 Aug 21; 58(4):245-53. PubMed ID: 20580167
    [Abstract] [Full Text] [Related]

  • 9. Risk assessment for the development of hepatocellular carcinoma: according to on-treatment viral response during long-term lamivudine therapy in hepatitis B virus-related liver disease.
    Eun JR, Lee HJ, Kim TN, Lee KS.
    J Hepatol; 2010 Jul 21; 53(1):118-25. PubMed ID: 20471129
    [Abstract] [Full Text] [Related]

  • 10. Prevention and surveillance of hepatitis B virus-related hepatocellular carcinoma.
    Liaw YF.
    Semin Liver Dis; 2005 Jul 21; 25 Suppl 1():40-7. PubMed ID: 16103980
    [Abstract] [Full Text] [Related]

  • 11. Chronic hepatitis B in Asia-new insights from the past decade.
    Chan HL, Jia J.
    J Gastroenterol Hepatol; 2011 Jan 21; 26 Suppl 1():131-7. PubMed ID: 21199524
    [Abstract] [Full Text] [Related]

  • 12. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Kim BK, Han KH, Ahn SH.
    Oncology; 2011 Jan 21; 81 Suppl 1():41-9. PubMed ID: 22212935
    [Abstract] [Full Text] [Related]

  • 13. The clinical implications of hepatitis B virus genotype: Recent advances.
    Lin CL, Kao JH.
    J Gastroenterol Hepatol; 2011 Jan 21; 26 Suppl 1():123-30. PubMed ID: 21199523
    [Abstract] [Full Text] [Related]

  • 14. A mathematical model to estimate global hepatitis B disease burden and vaccination impact.
    Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS.
    Int J Epidemiol; 2005 Dec 21; 34(6):1329-39. PubMed ID: 16249217
    [Abstract] [Full Text] [Related]

  • 15. Does antiviral therapy prevent hepatocellular carcinoma?
    Kwon H, Lok AS.
    Antivir Ther; 2011 Dec 21; 16(6):787-95. PubMed ID: 21900710
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.
    Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H.
    J Gastroenterol Hepatol; 2007 Nov 21; 22(11):1929-35. PubMed ID: 17914972
    [Abstract] [Full Text] [Related]

  • 17. Natural history of chronic hepatitis B REVEALed.
    Chen CJ, Yang HI.
    J Gastroenterol Hepatol; 2011 Apr 21; 26(4):628-38. PubMed ID: 21323729
    [Abstract] [Full Text] [Related]

  • 18. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease.
    Yuen MF, Seto WK, Chow DH, Tsui K, Wong DK, Ngai VW, Wong BC, Fung J, Yuen JC, Lai CL.
    Antivir Ther; 2007 Apr 21; 12(8):1295-303. PubMed ID: 18240869
    [Abstract] [Full Text] [Related]

  • 19. Hepatitis B vaccination in children: the Taiwan experience.
    Ni YH, Chen DS.
    Pathol Biol (Paris); 2010 Aug 21; 58(4):296-300. PubMed ID: 20116181
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.
    Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A.
    J Viral Hepat; 2013 Jul 21; 20(7):502-9. PubMed ID: 23730844
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 90.